STOCK TITAN

[Form 4] Vaxcyte, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vaxcyte, Inc. President and CFO Andrew Guggenhime reported an option exercise and related share sales. He exercised stock options to acquire 10,000 shares of Common Stock at $5.35 per share, then sold 10,000 shares in two open-market transactions.

The sales covered 2,087 shares at a weighted-average price of about $57.76 and 7,913 shares at a weighted-average price of about $57.16, with actual prices ranging from $56.595 to $58.32, pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026. Following these transactions, he holds 104,395 shares directly and 61,850 shares indirectly through ALG 2025 GRAT Holdings LLC.

Positive

  • None.

Negative

  • None.
Insider GUGGENHIME ANDREW
Role PRESIDENT AND CFO
Sold 10,000 shs ($573K)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 10,000 $0.00 --
Exercise Common Stock 10,000 $5.35 $54K
Sale Common Stock 7,913 $57.157 $452K
Sale Common Stock 2,087 $57.764 $121K
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 226,827 shares (Direct, null); Common Stock — 114,395 shares (Direct, null); Common Stock — 61,850 shares (Indirect, See Footnote)
Footnotes (1)
  1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026. The price reported is a weighted-average price. The shares were sold at prices ranging from $56.595 to $57.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $57.61 to $58.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee. Option is fully vested and exercisable.
Shares sold (block 1) 2,087 shares at $57.764 Open-market sale of Common Stock on July 6, 2026
Shares sold (block 2) 7,913 shares at $57.157 Open-market sale of Common Stock on July 6, 2026
Options exercised 10,000 shares at $5.35 Stock option exercise of Common Stock on July 6, 2026
Direct holdings after transactions 104,395 shares Common Stock directly owned following reported trades
Indirect holdings via ALG 2025 GRAT Holdings LLC 61,850 shares Common Stock held indirectly as reported in holding entry
Net shares sold 10,000 shares Net of 10,000 shares sold versus 10,000 shares exercised
Option expiration date May 11, 2030 Original expiration for stock option that was exercised
Rule 10b5-1 trading plan regulatory
"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported is a weighted-average price. The shares were sold at prices ranging from $56.595 to $57.59."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
grantor retained annuity trust financial
"100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee."
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
Stock Option (right to buy) financial
"Stock Option (right to buy) with underlying security title Common Stock and exercise price of $5.35."
annuitant financial
"The Reporting Person is the annuitant and the trustee of the grantor retained annuity trust."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GUGGENHIME ANDREW

(Last)(First)(Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300

(Street)
SAN CARLOS CALIFORNIA 94070

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
PRESIDENT AND CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/06/2026M10,000A$5.35114,395D
Common Stock07/06/2026S(1)7,913D$57.157(2)106,482D
Common Stock07/06/2026S(1)2,087D$57.764(3)104,395D
Common Stock61,850ISee Footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$5.3507/06/2026M10,000 (5)05/11/2030Common Stock10,000$0226,827D
Explanation of Responses:
1. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.
2. The price reported is a weighted-average price. The shares were sold at prices ranging from $56.595 to $57.59. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. The price reported is a weighted-average price. The shares were sold at prices ranging from $57.61 to $58.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
4. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.
5. Option is fully vested and exercisable.
Remarks:
Andrew Guggenhime, by /s/ Peter N. Efremenko, Attorney-In-Fact07/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)